Previous 10 | Next 10 |
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that a permanent J-c...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced its Annual Report on...
ADC Therapeutics SA (ADCT) Q4 2021 Earnings Conference Call March 3, 2022 08:30 ET Company Participants Amanda Hamilton - Investor Relations Officer Christopher Martin - Co-Founder & Chief Executive Officer Jennifer Creel - Chief Financial Officer Jennifer Herron - Chief Commercial Office...
Image source: The Motley Fool. ADC Therapeutics SA (NYSE: ADCT) Q4 2021 Earnings Call Mar 03, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: ADC Therapeutics SA (ADCT) Q4 2021 Earnings Call Transcript
The following slide deck was published by ADC Therapeutics SA in conjunction with their 2021 Q4 earnings call. For further details see: ADC Therapeutics SA 2021 Q4 - Results - Earnings Call Presentation
ADC Therapeutics press release (NYSE:ADCT): Q4 Non-GAAP EPS of -$0.39 beats by $0.49. Revenue of $17.01M beats by $0.54M. Shares +4.99% PM. For further details see: ADC Therapeutics Non-GAAP EPS of -$0.39 beats by $0.49, revenue of $17.01M beats by $0.54M
ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $17.0 million in the fourth quarter of 2021 and $33.9 million in FY 2021 following May launch LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA in combination with rituximab safety lead-in complete and now enrolli...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, D...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced that it will host a ...
Report documents ESG accomplishments and reflects commitment to corporate responsibility ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (AD...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...